Thomas V. Jones

1.8k total citations
49 papers, 1.4k citations indexed

About

Thomas V. Jones is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Thomas V. Jones has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Rheumatology, 15 papers in Immunology and 14 papers in Genetics. Recurrent topics in Thomas V. Jones's work include Rheumatoid Arthritis Research and Therapies (20 papers), Inflammatory Bowel Disease (14 papers) and Biosimilars and Bioanalytical Methods (11 papers). Thomas V. Jones is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Inflammatory Bowel Disease (14 papers) and Biosimilars and Bioanalytical Methods (11 papers). Thomas V. Jones collaborates with scholars based in United States, Spain and Canada. Thomas V. Jones's co-authors include Martha Gerrity, JoAnne Earp, Nervin Lawendy, Chinyu Su, Bruce E. Sands, Julián Panés, William J. Sandborn, Gary S. Friedman, Geert D’Haens and Michele Moscariello and has published in prestigious journals such as Gastroenterology, The American Journal of Medicine and Journal of Clinical Epidemiology.

In The Last Decade

Thomas V. Jones

48 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas V. Jones United States 16 445 436 408 273 227 49 1.4k
Thomas Mittendorf Germany 23 441 1.0× 167 0.4× 308 0.8× 253 0.9× 160 0.7× 105 1.7k
Haijun Tian United States 22 542 1.2× 115 0.3× 243 0.6× 374 1.4× 88 0.4× 52 1.5k
Ross Maclean United States 20 811 1.8× 152 0.3× 151 0.4× 171 0.6× 397 1.7× 38 1.6k
Elizabeth D. Ferucci United States 21 745 1.7× 82 0.2× 144 0.4× 226 0.8× 178 0.8× 54 1.5k
David J. Tunnicliffe Australia 18 323 0.7× 145 0.3× 72 0.2× 135 0.5× 82 0.4× 69 1.2k
Roos Colman Belgium 21 361 0.8× 99 0.2× 124 0.3× 195 0.7× 119 0.5× 50 1.4k
Teresa A. Simon United States 24 1.1k 2.5× 58 0.1× 454 1.1× 335 1.2× 429 1.9× 68 2.5k
Carolyn E. Behrendt United States 19 62 0.1× 77 0.2× 483 1.2× 272 1.0× 117 0.5× 44 1.5k
Mariëlle Romberg‐Camps Netherlands 24 68 0.2× 1.4k 3.2× 1.1k 2.7× 200 0.7× 78 0.3× 68 2.0k
Sue Langham United Kingdom 18 165 0.4× 114 0.3× 193 0.5× 143 0.5× 39 0.2× 48 1.1k

Countries citing papers authored by Thomas V. Jones

Since Specialization
Citations

This map shows the geographic impact of Thomas V. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas V. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas V. Jones more than expected).

Fields of papers citing papers by Thomas V. Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas V. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas V. Jones. The network helps show where Thomas V. Jones may publish in the future.

Co-authorship network of co-authors of Thomas V. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas V. Jones. A scholar is included among the top collaborators of Thomas V. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas V. Jones. Thomas V. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winthrop, Kevin, Arne Yndestad, Dan Henrohn, et al.. (2022). Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and Therapy. 10(2). 357–373. 3 indexed citations
2.
3.
Burmester, Gerd R, Jeffrey R. Curtis, Huifeng Yun, et al.. (2020). An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Safety. 43(4). 379–392. 34 indexed citations
4.
Mease, Philip J., Christina Charles‐Schoeman, Stanley Cohen, et al.. (2020). Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Annals of the Rheumatic Diseases. 79(11). 1400–1413. 153 indexed citations
5.
Sandborn, W., Julián Panés, G. D’Haens, et al.. (2019). A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS. Journal of the Canadian Association of Gastroenterology. 2(Supplement_2). 396–397. 1 indexed citations
6.
Rigby, William F. C., Gerd R Burmester, Oliver FitzGerald, et al.. (2018). Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Queensland's institutional digital repository (The University of Queensland). 70. 1 indexed citations
7.
8.
Sandborn, William J., Julián Panés, Geert D’Haens, et al.. (2018). Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clinical Gastroenterology and Hepatology. 17(8). 1541–1550. 193 indexed citations
9.
Smolen, Josef S, Annette Szumski, Andrew Koenig, Thomas V. Jones, & Lisa Marshall. (2018). Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Research & Therapy. 20(1). 8–8. 29 indexed citations
10.
11.
Mease, Philip J., Joel M. Kremer, Stanley Cohen, et al.. (2018). SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. Annals of the Rheumatic Diseases. 77. 983–983. 7 indexed citations
12.
13.
Genovese, Mark C., Ronald van Vollenhoven, Bethanie Wilkinson, et al.. (2016). Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Research & Therapy. 18(1). 145–145. 15 indexed citations
14.
Smolen, Josef S, Vibeke Strand, Andrew Koenig, et al.. (2016). Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Research & Therapy. 18(1). 114–114. 47 indexed citations
15.
Jones, Thomas V., Michael J. Siegel, & John R. Schneider. (1998). Recognition and Management of Oral Health Problems in Older Adults by Physicians: A Pilot Study. The Journal of the American Board of Family Medicine. 11(6). 474–477. 7 indexed citations
16.
Adams, Wendy L. & Thomas V. Jones. (1998). Alcohol and injuries in elderly people. Addiction Biology. 3(3). 237–247. 6 indexed citations
17.
Jones, Thomas V., et al.. (1996). Performance of alcoholism screening questionnaires in elderly veterans. The American Journal of Medicine. 101(2). 153–159. 77 indexed citations
18.
Jones, Thomas V., et al.. (1993). Alcoholism screening questionnaires. Journal of General Internal Medicine. 8(12). 674–678. 66 indexed citations
19.
Jones, Thomas V., Martha Gerrity, & JoAnne Earp. (1990). Written case simulations: Do they predict physicians' behavior?. Journal of Clinical Epidemiology. 43(8). 805–815. 206 indexed citations
20.
Jones, Thomas V., et al.. (1988). Rethinking the Approach to Evaluating Mental Functioning of Older Persons The Value of Careful Observations. Journal of the American Geriatrics Society. 36(12). 1128–1134. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Mittendorf Breakdown of academic impact, for papers by Haijun Tian Breakdown of academic impact, for papers by Ross Maclean Breakdown of academic impact, for papers by Elizabeth D. Ferucci Breakdown of academic impact, for papers by David J. Tunnicliffe Breakdown of academic impact, for papers by Roos Colman Breakdown of academic impact, for papers by Teresa A. Simon Breakdown of academic impact, for papers by Carolyn E. Behrendt Breakdown of academic impact, for papers by Mariëlle Romberg‐Camps Breakdown of academic impact, for papers by Sue Langham
Rankless by CCL
2026